Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
288
Completed, industry sponsors, Kidney and urology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed288
288 trials
Showing 1 to 25, recently updated first.
DiaMedica Therapeutics IncIndustry
NCT04123613 · 84 participants · Start Dec 17, 2019 · Primary completion Mar 16, 2022
Drug: DM199 · For: Kidney Diseases
Sites: Mesa, Arizona; Granada Hills, California; Los Angeles, California · 14 sites in all
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05936151 · 146 participants · Start Jul 20, 2023 · Primary completion Oct 1, 2025
Drug: Retatrutide; Placebo · For: Overweight or Obesity; CKD; Type 2 Diabetes
Sites: Chandler, Arizona; Mesa, Arizona; Scottsdale, Arizona · 42 sites in all
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06926660 · 492 participants · Start Jul 18, 2025 · Primary completion Aug 14, 2026
Drug: Vicadrostat; Empagliflozin and 1 more · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Anaheim, California; San Dimas, California · 157 sites in all
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07634744 · 25 participants · Start Dec 31, 2024 · Primary completion Apr 23, 2026
Drug: XH-S003 Capsule · For: IgA Nephropathy
Sites: Beijing, China
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06131372 · 626 participants · Start Apr 1, 2024 · Primary completion Sep 24, 2025
Drug: Cagrilintide; Semaglutide and 1 more · For: Chronic Kidney Disease; Type 2 Diabetes; Obesity
Sites: Concord, California; Fresno, California; Palm Springs, California · 129 sites in all
- A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05536804 · 134 participants · Start Feb 8, 2023 · Primary completion Jul 6, 2026
Drug: Tirzepatide; Placebo · For: Overweight; Obesity; Chronic Kidney Disease and 2 more
Sites: Northridge, California; Aurora, Colorado; Denver, Colorado · 27 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06794996 · 42 participants · Start Feb 4, 2025 · Primary completion Jul 20, 2026
Drug: Inaxaplin · For: Proteinuric Kidney Disease
Sites: Huntsville, Alabama; Hollywood, Florida; Lauderdale Lakes, Florida · 35 sites in all
- A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRPPivotal-lookingCompleted
Tourmaline Bio, Inc., a Novartis CompanyIndustry
NCT06362759 · 143 participants · Start May 15, 2024 · Primary completion Mar 6, 2025
Drug: TOUR006 - 50 MG; TOUR006 - 25 MG and 1 more · For: Chronic Kidney Diseases; Chronic Kidney Insufficiency; Chronic Renal Diseases and 6 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 38 sites in all
- A Trial of HRS-5965 Tablets in Primary IgA NephropathyPivotal-lookingCompleted
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06137768 · 123 participants · Start Dec 19, 2023 · Primary completion Oct 17, 2025
Drug: HRS-5965; Placebo · For: Primary IgA Nephropathy
Sites: Beijing, China
- MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney DiseasePivotal-lookingCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT06690242 · 115 participants · Start Nov 4, 2024 · Primary completion Aug 30, 2025
Drug: MT1013; MT1013 and 2 more · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Hangzhou, China
Novartis PharmaceuticalsNovartis (NVS)
NCT05834738 · 54 participants · Start Jul 20, 2023 · Primary completion Jun 30, 2025
Drug: Atrasentan; Atrasentan and 1 more · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Atlanta, Georgia; Oak Brook, Illinois · 30 sites in all
BayerBayer (BAYRY)
NCT05254002 · 1,664 participants · Start Jun 23, 2022 · Primary completion Mar 14, 2025
Drug: Finerenone (BAY94-8862 ) 10 mg; Empagliflozin and 3 more · For: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Sites: Surprise, Arizona; Los Angeles, California; Northridge, California · 173 sites in all
- Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney DiseasePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06350123 · 324 participants · Start May 1, 2024 · Primary completion May 9, 2025
Drug: Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg; Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg and 1 more · For: Chronic Kidney Disease
Sites: Sheffield, Alabama; Glendale, California; Waterbury, Connecticut · 92 sites in all
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03945318 · 103 participants · Start Apr 8, 2019 · Primary completion Jun 10, 2026
Drug: BION-1301 Single Dose; Placebo Single Dose and 3 more · For: IgA Nephropathy
Sites: Northridge, California; Denver, Colorado; Orlando, Florida · 16 sites in all
Mineralys Therapeutics Inc.Industry
NCT06150924 · 60 participants · Start Dec 14, 2023 · Primary completion Feb 27, 2025
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD; Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD · For: Chronic Kidney Disease
Sites: Glendale, Arizona; Phoenix, Arizona; Chula Vista, California · 44 sites in all
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06670352 · 87 participants · Start Oct 12, 2024 · Primary completion Dec 20, 2025
Drug: Placebo; HSK39297 50mgBID and 2 more · For: IgA Nephropathy (IgAN)
Sites: Beijing, China; Nanjing, China
- Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseaseCompleted
Arrowhead PharmaceuticalsIndustry
NCT05083364 · 62 participants · Start Feb 1, 2022 · Primary completion Sep 10, 2025
Drug: ARO-C3; Placebo · For: C3 Glomerulopathy; IgA Nephropathy
Sites: Camperdown, Australia; Concord, Australia; Clayton, Australia · 16 sites in all
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06236295 · 303 participants · Start Feb 20, 2024 · Primary completion Nov 13, 2025
Drug: SHR6508 · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Beijing, China
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04626505 · 36 participants · Start Oct 22, 2020 · Primary completion Aug 3, 2021
Drug: Ziltivekimab; Placebo (ziltivekimab) · For: Chronic Kidney Disease; Inflammation; Cardiovascular Risk
Sites: Ehime, Japan
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusPivotal-lookingCompleted
Galderma R&DIndustry
NCT05075408 · 258 participants · Start Mar 18, 2022 · Primary completion Jan 4, 2024
Drug: Nemolizumab; Nemolizumab and 1 more · For: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Sites: Bakersfield, California; Glendale, California; La Palma, California · 64 sites in all
HI-Bio, A Biogen CompanyIndustry
NCT05065970 · 54 participants · Start Aug 31, 2021 · Primary completion Feb 6, 2023
Drug: Felzartamab · For: Immunoglobulin A (IgA) Nephropathy
Sites: Oxnard, California; Vacaville, California; Rochester, Minnesota · 59 sites in all
- Safety and Efficacy Study of VIS649 for IgA NephropathyPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT04287985 · 155 participants · Start Jul 20, 2020 · Primary completion May 19, 2023
Drug: Dose-Placebo; Low Dose-VIS649 and 2 more · For: Immunoglobulin A Nephropathy; Glomerular Disease; IgAN
Sites: Birmingham, Alabama; Los Angeles, California; Oxnard, California · 93 sites in all
- A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT06522997 · 1,222 participants · Start Aug 8, 2024 · Primary completion Oct 24, 2025
Drug: BAY3283142; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Chula Vista, California; San Dimas, California · 153 sites in all
ProkidneyIndustry
NCT05018416 · 53 participants · Start Jul 27, 2021 · Primary completion May 20, 2025
Drug: Renal Autologous Cell Therapy (REACT) · For: Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
Sites: Denver, Colorado; Newark, Delaware; Nampa, Idaho · 5 sites in all
- A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.Pivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05016323 · 316 participants · Start Sep 9, 2021 · Primary completion Jun 9, 2024
Drug: HR19042 Capsules; Placebo · For: IgA Nephropathy
Sites: Guangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.